{
  "_metadata": {
    "version": "2.0",
    "ticker": "ARGX",
    "asset_name": "efgartigimod"
  },
  "asset": {
    "name": "efgartigimod (VYVGART)",
    "ticker": "ARGX",
    "modality": "Fc fragment (human IgG1 Fc engineered for FcRn binding)",
    "stage": "Approved + Phase 3 expansion",
    "one_liner": "First-in-class FcRn inhibitor approved for gMG and CIDP, with 6 additional registrational programs and ~19K patients treated globally",
    "ownership": "Wholly-owned",
    "brand_names": "VYVGART (IV), VYVGART Hytrulo (SC)"
  },
  "target": {
    "name": "FcRn",
    "full_name": "Neonatal Fc Receptor",
    "class": "Receptor/Transporter",
    "pathway": "FcRn recycles IgG → blocking FcRn accelerates IgG degradation → reduces pathogenic autoantibodies",
    "biology": {
      "simple_explanation": "FcRn is responsible for recycling IgG antibodies, extending their half-life. Blocking FcRn leads to accelerated degradation of IgG, including pathogenic autoantibodies that cause autoimmune diseases. This provides rapid, reversible reduction in disease-causing antibodies.",
      "igg_reduction": "60-80% reduction in total IgG levels",
      "selectivity": "Does not affect IgA, IgM, or IgE; does not deplete B cells"
    },
    "why_good_target": {
      "clinical_validation": "Validated by success of IVIg and plasmapheresis; efgartigimod approved in gMG and CIDP",
      "unmet_need": [
        "IVIg has supply constraints and infusion burden",
        "Plasmapheresis requires specialized centers",
        "B cell depletion has slow onset and infection risk",
        "Many autoimmune diseases lack targeted therapies"
      ]
    }
  },
  "indications": {
    "lead": {
      "name": "Generalized Myasthenia Gravis (gMG)",
      "stage": "Approved (Dec 2021)",
      "rationale": "First approval; AChR+ gMG patients with clear autoantibody-driven pathology"
    },
    "approved": [
      {
        "name": "gMG (AChR+)",
        "approval_date": "December 2021",
        "markets": "US, EU, Japan, 40+ countries"
      },
      {
        "name": "CIDP",
        "approval_date": "2024",
        "status": "Blockbuster as of 3Q 2025"
      }
    ],
    "registrational": [
      {
        "name": "Seronegative gMG (MuSK+, LRP4+, triple seronegative)",
        "stage": "Decision by end of 2026"
      },
      {
        "name": "Ocular MG",
        "stage": "Phase 3 ADAPT-Oculus",
        "readout": "1Q 2026"
      },
      {
        "name": "Autoimmune Myositis",
        "stage": "Phase 3 ALKIVIA",
        "readout": "3Q 2026"
      },
      {
        "name": "ITP",
        "stage": "Phase 3 ADVANCE-NEXT",
        "readout": "4Q 2026"
      },
      {
        "name": "Sjögren's Disease",
        "stage": "Phase 3 UNITY",
        "readout": "2H 2027"
      },
      {
        "name": "Graves' Disease",
        "stage": "Registrational"
      }
    ]
  },
  "clinical_data": {
    "trial_name": "Multiple registrational programs",
    "trial_design": {
      "phase": "Approved + 6 ongoing Phase 3",
      "design": "Randomized, double-blind, placebo-controlled pivotal trials",
      "formulations": "IV infusion, SC Hytrulo, Prefilled syringe (approved)"
    },
    "commercial_results": {
      "global_patients_treated": "~19,000",
      "us_prescribers": ">4,700",
      "prescriber_growth": "20% YoY increase",
      "mg_position": "#1 prescribed biologic",
      "mg_market_impact": "Drove 60% growth in overall MG biologics share",
      "cidp_status": "Blockbuster as of 3Q 2025"
    },
    "upcoming_readouts": {
      "ocular_mg": "1Q 2026 - MGII novel primary endpoint",
      "myositis": "3Q 2026 - TIS composite primary endpoint",
      "itp": "4Q 2026 - Cumulative platelet count endpoint",
      "sjogrens": "2H 2027 - Challenging primary endpoint"
    },
    "safety": {
      "profile": "Generally well-tolerated across indications",
      "key_considerations": "IgG reduction may increase infection risk; infusion/injection site reactions; headache"
    }
  },
  "formulations": {
    "current": [
      "VYVGART IV infusion",
      "VYVGART Hytrulo SC (Halozyme ENHANZE)",
      "Prefilled syringe (approved)"
    ],
    "development": [
      "Autoinjector (est. 2027, Ypsomed)",
      "Small volume delivery (Elektrofi partnership)",
      "Oral peptides (Unnatural Products partnership)"
    ]
  },
  "catalysts": [
    {
      "event": "Ocular MG Phase 3 readout",
      "timing": "1Q 2026",
      "importance": "critical",
      "what_to_watch": "MGII primary endpoint; first and only Ocular MG development"
    },
    {
      "event": "Myositis Phase 3 readout",
      "timing": "3Q 2026",
      "importance": "critical",
      "what_to_watch": "TIS composite in heterogeneous disease; 70K US patient opportunity"
    },
    {
      "event": "ITP Phase 3 readout",
      "timing": "4Q 2026",
      "importance": "high",
      "what_to_watch": "Cumulative platelet count in difficult-to-treat patients"
    },
    {
      "event": "Seronegative MG approval",
      "timing": "By end of 2026",
      "importance": "high",
      "what_to_watch": "Broadest MG label; +11K addressable patients"
    },
    {
      "event": "Sjögren's Phase 3 readout",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "330K US prevalence; challenging endpoint"
    }
  ],
  "competitive_landscape": {
    "fcrn_inhibitors": [
      {
        "drug": "RYSTIGGO (rozanolixizumab)",
        "company": "UCB",
        "status": "Approved gMG",
        "limitation": "Later entrant; less real-world experience"
      },
      {
        "drug": "nipocalimab",
        "company": "J&J",
        "status": "Phase 3 gMG",
        "limitation": "Not yet approved"
      },
      {
        "drug": "batoclimab",
        "company": "Immunovant/HarbourBio",
        "status": "Phase 3",
        "limitation": "Not yet approved"
      }
    ],
    "vyvgart_advantages": [
      "First-in-class with most real-world experience (~19K patients)",
      "Multiple formulations (IV, SC, PFS; autoinjector coming)",
      "Broadest clinical development (15+ indications)",
      "Next-gen FcRn molecules in pipeline (ARGX-213, ARGX-124)"
    ]
  },
  "investment_analysis": {
    "probability_of_success": "Approved product with expansion optionality",
    "peak_sales_estimate": "$10B+ across all indications",
    "key_risks": [
      "FcRn competition from UCB, J&J, Immunovant",
      "Phase 3 execution in heterogeneous diseases",
      "Maintaining market share as competitors launch"
    ]
  },
  "market_opportunity": {
    "mg_us_2030": "60K addressable patients (vs 17K at launch)",
    "cidp_us": "42K diagnosed patients",
    "myositis_us": "70K patients",
    "sjogrens_us": "330K patients (100K moderate-severe)",
    "total_opportunity": "$10B+ peak sales potential"
  }
}
